Positive Phase 1 trial data for vispa-cel, an allogeneic (off-the-shelf) CAR-T cell therapy, demonstrates efficacy and durability comparable to traditional autologous treatments, potentially broadenin...

Using AI to find stock market opportunities. Click to read StockQuakes, by StockQuakes Team, a Substack publication with hundreds of subscribers.

Caribou Biosciences (Nasdaq: CRBU) reported first clinical data from the CaMMouflage Phase 1 trial of CB-011 in relapsed or refractory multiple myeloma. The 450x10^6 CAR-T cell dose is the recommended dose for expansion (RDE); dose expansion is planned to start by year-end with data expected in 2026. In 12 BCMA-naïve patients at the RDE (median follow-up 8.3 months) the trial showed 92% ORR, 75% ≥CR, and 91% MRD negativity (≤10^-5). Safety was described as manageable but included cytopenias, infections and isolated serious adverse events.

The FDA is unveiling a faster approval pathway for custom gene-editing therapies, aiming to spark major investment and accelerate cures for rare diseases through Crispr-based innovations.

YouTube video by EO(エオ)

YouTube video by supersam979

Biotech is entering a new phase of growth in summer 2025, backed by scientific momentum, clinical progress, and a more favorable investment landscape. Following a challenging few years, the sector is rebounding as interest rates ease and investors return to innovative, high-conviction names with late-stage programs and differentiated platforms. New technologies are accelerating timelines across the board. AI is helping to identify drug targets and biomarkers with greater precision.

YouTube video by VRC DJ LIVE

Caribou Biosciences (NASDAQ: CRBU) reported Q1 2025 financial results and provided updates on its clinical programs. The company ended Q1 with $212.5 million in cash and equivalents, expected to fund operations into H2 2027. Caribou reported a net loss of $40.0 million for Q1 2025.The company recently implemented strategic pipeline prioritization, focusing on its lead oncology programs CB-010 and CB-011, while discontinuing other trials. This resulted in a 32% workforce reduction with estimated cash payments of $2.5-3.5 million.Key upcoming milestones include two clinical datasets in H2 2025: CB-010's ANTLER trial data from a 20-patient cohort in large B cell lymphoma, and CB-011's CaMMouflage trial data from at least 25 multiple myeloma patients at multiple dose levels.

Get more from THE OPTIONS BULLY on Patreon

Strategic shift focuses on CB-010 and CB-011 cancer programs, cuts 32% workforce, and extends $212.5M cash runway. See full restructuring impact.

Caribou Biosciences (NASDAQ: CRBU) has reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical pipeline. The company ended 2024 with $249.4 million in cash and equivalents, expected to fund operations into H2 2026.Key financial metrics include:Q4 2024 revenue: $2.1 millionFull year 2024 revenue: $10.0 millionQ4 2024 net loss: $35.5 millionFull year 2024 net loss: $149.1 millionThe company anticipates two major clinical data releases in H1 2025: results from the ANTLER Phase 1 trial of CB-010 in second-line large B cell lymphoma and initial data from the CaMMouflage Phase 1 trial of CB-011 in relapsed/refractory multiple myeloma. The company is advancing four clinical programs across hematologic malignancies and autoimmune diseases.

If you are a shareholder of Caribou Biosciences, Inc., it's crucial to reach out to The Gross Law Firm by February 24, 2025, to discuss your rights and potential actions regarding your shares.

CRBU DEADLINE ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Caribou Biosciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 24 Deadline in

El partido que el Atlético de Madrid disputó ante el Valencia en Mestalla, no se escapó de esta tendencia de polémicas arbitrales que se vive últimamente en LaLiga.

Levi & Korsinsky, LLP is alerting Caribou Biosciences investors about a class action lawsuit aimed at addressing alleged securities fraud, with a deadline for participation by February 24, 2025.